OptiMedica donates photocoagulator to ORBIS

Article

OptiMedica Corp has donated a PASCAL photocoagulator to non-profit organization ORBIS International, under a new partnership between the two companies.

OptiMedica Corp has donated a PASCAL photocoagulator to non-profit organization ORBIS International, under a new partnership between the two organizations.

The PASCAL photocoagulator, which decreases the duration and frequency of photocoagulation while increasing the safety, comfort and efficiency of the procedure, will be used onboard ORBIS's Flying Eye Hospital to train doctors in the developing world to treat retinal disorders, particularly diabetic retinopathy.

The technology was first used by ORBIS on the Flying Eye Hospital's first visit to Laos, a country with 25 ophthalmologists and 30,000 blind among the population of six million. The visit concluded on January 30th and was attended by an engineer from OptiMedica.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.